Abstract

New Developments in the Management of Borderline Resectable Pancreatic Cancers

There remains great variability in the treatment for patients with borderline resectable pancreatic head cancers. Whethersurgery should be attempted or neoadjuvant therapy consisting of chemoradiation or chemotherapy alone is at some debate. Each neoadjuvant regimen does show efficacy but there is no clear consensus which would be most beneficial. We will discuss three abstracts (#4043, #4057, #e15082) that were presented in the 2013 ASCO Annual Meeting that will discuss neoadjuvant therapies and how they are related to getting an R0 resection.


Author(s):

Muhammad Wasif Saif, Kathryn Huber, Martin D Goodman, Sarah McPartland



Abstract | Full-Text | PDF

Share this  Facebook  Twitter  LinkedIn  Google+

Abstracted/Indexed in

  • Index Copernicus
  • Academic Journals Database
  • Genamics JournalSeek
  • Academic Keys
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Scimago
  • British Library
  • Electronic Journals Library
  • Directory of Research Journal Indexing (DRJI)
  • WorldCat
  • Emerging Sources Citation Index (ESCI)
  • EBSCO Host
  • MIAR
  • International Committee of Medical Journal Editors (ICMJE)
  • University of Zurich - UZH
  • University Grants Commission
  • SWB Online-Katalog
  • Scholarsteer
  • Geneva Foundation for Medical Education and Research
  • Secret Search Engine Labs
Flyer image